Skip Navigation

Annals of Oncology 2007 18(Supplement 5):v9-v15; doi:10.1093/annonc/mdm173
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fumoleau, P
Right arrow Articles by Ferrant, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fumoleau, P
Right arrow Articles by Ferrant, E
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

articles

Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues

P Fumoleau*, B Coudert, N Isambert and E Ferrant

Medical Oncology Department, Centre Georges-François Leclerc, Dijon, France

* Correspondence to: Dr P. Fumoleau, Centre Georges-François Leclerc, 1, Rue Professeur Marion, BP 77 908 21034, Dijon Cedex, France. Tel: +33-3-80-73-75-06; Fax: +33-3-80-73-77-16; E-mail: pfumoleau{at}dijon.fnclcc.fr

Background: Epothilones are 16-member ring macrolides with antimicrotubule activity that share a similar mechanism of action to the taxanes but have demonstrated potent antiproliferative activity in several different multidrug-resistant and paclitaxel-resistant tumor cell lines in vitro and in vivo.

Design: This review summarizes data from preclinical and phase I clinical studies of epothilone B (patupilone; EPO960) and epothilone D (KOS-862) and their second-generation (ixabepilone, BMS-310705, KOS-1584) and third-generation (ZK-EPO, ABJ-879) derivatives. Data were identified by searches of PubMed and the Proceedings of the American Society of Clinical Oncology annual meetings from 2000 to 2006.

Results: Epothilones demonstrate a linear dose-dependent pharmacokinetic profile, are well tolerated, and exhibit antitumor activity in a variety of tumor types in phase I studies of patients with cancer. Although similar in chemical structure, the epothilones demonstrate a striking difference in toxicity profile in phase I studies. Diarrhea is the dose-limiting toxicity (DLT) associated with patupilone, whereas neurotoxicity and neutropenia are the DLTs most commonly encountered with other epothilones. Consistent with preclinical data, partial responses were observed with patupilone and ixabepilone in patients with breast cancer previously treated with taxanes.

Conclusion: The epothilones demonstrate promising antitumor activity in a broad spectrum of taxane-sensitive and -refractory tumors at doses and schedules associated with tolerable side-effects.

Key words: epothilone, mechanism of action, phase I study, preclinical, tubulin-targeting agents


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
J. Hoffmann, I. Vitale, B. Buchmann, L. Galluzzi, W. Schwede, L. Senovilla, W. Skuballa, S. Vivet, R. B. Lichtner, J. M. Vicencio, et al.
Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
Cancer Res., July 1, 2008; 68(13): 5301 - 5308.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.